Message from Dr. Gomez

-


Messages from Dr. Gomez and Hannah Casey (research lead for this project): 

Dear SCA6 Network Members,

From Dr. Gomez:  Thank you very much to all of those who have filled out our survey. The questions on this very long survey have been collected to a large extent from the questions you all have asked me over the years. Our intention is to get answers from a large number of people in order for me to give informative replies to patients' questions in the future. We have been doing reasonably well, but we still have many more surveys to receive. The SCA6 network includes about 350 people. So far I have only received electronic surveys from 130 people. This is many more than the paper survey we conducted previously, but to really learn something, we have many more to go.  Can you please let us know when you complete the survey or let us know what trouble you’re having with completing it. Thank you very much.

From Hannah: 'Another email reminder would be greatly appreciated. We are currently stalled around 130 surveys. If you could also, please make a note to have people prepared to include their genetic results when they fill in the survey or remember to add them. There are about 30 people that have indicated that they are genetically diagnosed with SCA6 but exited the survey at the genetics question (these 30 are not included in the 130). If they have any questions about genetic results/alleles, they can email me, hannahcasey@uchicago.edu, and I am happy to walk them through what information they need to enter.'

Best wishes,

Christopher M. Gomez, M.D., Ph.D.
Albina Y. Surbis Professor
Department of Neurology
The University of Chicago

Administrative Assistant:  Debra Murphy
dmurphy2@bsd.uchicago.edu
Lab: J219, J255
https://voices.uchicago.edu/gomezlab/
http://ataxia.uchicago.edu
http://sca6.org/

Hannah Casey | Senior Analyst, Clinical Research

Department of Neurology

The University of Chicago Biological Sciences Division 

5841 South Maryland Avenue |MC 2030, Room A219 |Chicago, IL 60637

Office: 773.702.4610

Primary Email: hannahcasey@uchicago.edu

Alternative Email: hannahcasey@bsd.uchicago.edu 


Thank you all for participating to help answer these questions we all have!


Take care,

Terry

Comments

Post a Comment

Popular posts from this blog

Sadness

-
Image
  You might think, from these postings, that I have the greatest ataxia attitude ever.  But I have my days.  Today I can’t stop crying. This is an incredibly difficult thing to deal with.  Everyone with ataxia (unless they’re in complete denial) has days like this.  Today all my advice about meditation and exercise is out the window.  It’s a grieving day. Some of you may have gotten annoyed with my happy talk.  Please read my posts on Rage, Suicide, Depression.  Happy talk?  As Sheryl Crow said, “No one said this would be easy.” I have no advice for days like this.  They happen.  I just need to ride this out.  I bought black-out shades for my room so I’m going to my dark hole.
Read more

Hi there!

-
Image
 I’m back, bitches!  I’m much worse and have lots to say. I was diagnosed with some type of cerebellar ataxia in 1988.  I was confirmed as SCA6 in 1998 by genetic bloodwork. Here’s a cute dog picture.  The big one is Dasher and she is a trained service dog 🦮.  The puppy is Jax and she is a service dog in training 🐾.  I will have much more to say about service dogs for ataxians later.
Read more

Trials

-
Image
I hope you all are doing well. I was just checking up on ataxia trial news. If you ever want to check out what is going on yourself, google  clinicaltrials.gov  and just type in SCA6 or whatever disease you are interested in into the search box. Doing this reminded me that the PRIME-Ataxia exercise study is recruiting. This study allows remote participation (flyer attached). I also listened to a video about how the first FDA approval of a medicine to help with  Freidrich's ataxia  came about. In the video, the company scientist described the importance of having a robust disease life history database and patient advocacy. https://www.ataxia.org/fda-approves-first-treatment-for-friedreichs-ataxia/ The FDA recently the FDA announced approval for  SKYCLARYS  (omaveloxolone) for the treatment of Friedreich’s Ataxia. This is the first and only FDA-approved prescription medicine for Friedreich’s Ataxia (FA). NAF is thrilled about this announcement and proud ...
Read more